Abstract
Budesonide/formoterol maintenance and reliever therapy (Symbicort SMART) is an effective asthma-management regime where patients use budesonide/formoterol both as maintenance treatment and as additional doses as needed to improve overall asthma control by reducing symptoms and exacerbations. The aim of this study was to determine the cost-effectiveness of the Symbicort SMART regime in Denmark vs higher dose inhaled corticosteroid (ICS) plus reliever medication, similar dose inhaled corticosteroid/long-acting beta(2)-agonist (ICS/LABA) combination therapy plus reliever medication or higher dose of inhaled ICS/LABA combination therapy plus reliever medication.
| Original language | English |
|---|---|
| Journal | The clinical respiratory journal |
| Volume | 3 |
| Issue number | 3 |
| Pages (from-to) | 169-80 |
| Number of pages | 11 |
| DOIs | |
| Publication status | Published - 2009 |
Keywords
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Asthma
- Bronchodilator Agents
- Budesonide
- Child
- Cost of Illness
- Cost-Benefit Analysis
- Denmark
- Drug Combinations
- Drug Therapy, Combination
- Economics, Pharmaceutical
- Ethanolamines
- Female
- Humans
- Male
- Middle Aged
- Multicenter Studies as Topic
- Randomized Controlled Trials as Topic
Fingerprint
Dive into the research topics of 'Cost-effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy in Denmark--cost-effectiveness analysis based on five randomised controlled trials'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS